Dr. Vaikom Mahadevan, MD

Dr. Mahadevan practices at Stockton Endoscopy Center in Stockton, California.

Dr. Mahadevan's NPI, 1659780914, was assigned on August 11, 2014. Dr. Mahadevan holds Massachusetts license 1013672.

Dr. Mahadevan's primary practice is Stockton Endoscopy Center, at 415 E Harding Way, Stockton, CA 95204 in San Joaquin County. The practice phone is (209) 942-1179.

Dr. Mahadevan's primary practice is Stockton Endoscopy Center in Stockton, California. Dr. Mahadevan is also affiliated with Dignity Health - St. Joseph's Medical Center. The medical group on file is Stockton Cardiology Medical Group. Dmand AI also links Dr. Mahadevan to 4 more hospitals, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mahadevan practices, 6 sites in all. Vendor and product names are available with a free account.

Interventional cardiology is Dr. Mahadevan's primary specialty in the NPI Registry, under taxonomy code 207RI0011X. Dr. Mahadevan is licensed in Massachusetts.

CMS data shows 245 Medicare services from Dr. Mahadevan across 10 procedure codes in 2024, for 135 Medicare patients. Medicare paid $30,994 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 135 Medicare patients who saw Dr. Mahadevan in 2024. The largest group is 75 to 84, with 47 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 24% are also on Medicaid. Their average risk score is 2.32, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mahadevan's median patient age at 68, with 47% women.

In 2024, Dr. Mahadevan wrote 67 Medicare Part D claims for 14 patients. 91% of them were for generic drugs. CMS names the drug for 28 of them, across 2 drugs with 11 or more claims each, at $515 in total drug cost. In 2023, CMS named 14 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Mahadevan for performance year 2024, reported through an alternative payment model (APM). Dr. Mahadevan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mahadevan as offering telehealth.

Coronary angioplasty and stenting: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 92 papers to Dr. Mahadevan, published from 2011 to 2025. 2022 was the busiest year, with 9. The most frequent topics are Cardiac Catheterization, Heart Defects, Congenital and Heart Valve Prosthesis Implantation. Dr. Mahadevan has published most often in Int J Cardiol. Dr. Mahadevan's most frequent co-authors are Harsh Agrawal, MD, Anushree Agarwal, MD and Sarah Blissett, MD.

Dmand AI links Dr. Mahadevan to 6 clinical trials. 5 are still active or recruiting. Conditions studied include Mitral Valve Insufficiency, Heart Valve Diseases and Foramen Ovale, Patent. Abbott Medical Devices sponsors the most, 3.

CMS Open Payments shows 583 general payments to Dr. Mahadevan from 21 drug and device companies from 2016 to 2025. Honoraria make up the largest share, 29% of the total. Edwards Lifesciences Corporation paid the most, $56,611.